Compare Natera Inc. Common Stock (NTRA) vs Rivian Automotive, Inc. (RIVN) Price & Performance

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.

Rivian Automotive (RIVN) trades at $12.95, down 4.36% amid a bearish technical signal despite beating Q3 2026 delivery estimates with 19,248 vehicles. The company maintains negative profitability with a net income margin of -54.95% but shows improving revenue trends, reaching $5.39 billion in 2025. Cash flow remains negative, though operational losses have narrowed significantly from previous years.

The stock presents a high-risk opportunity with Wall Street consensus leaning bullish (48% buy ratings) and a $16.89 price target, implying potential upside. Key risks include persistent cash burn, intense EV competition, and execution challenges in scaling R2 production and autonomy technology, which are critical for achieving profitability.